The UK’s National Institute for Health and Care Excellence (NICE) recently released draft guidance indicating that they will not approve Aimovig (erenumab) for coverage through the country’s National Health Service. While those prescribed Aimovig, a CGRP inhibitor produced by Novartis/Amgen, may pay out-of-pocket to receive the treatment, the cost of the medicine will keep many patients from accessing this long awaited, migraine prevention medication in the UK.
CHAMP stands with the UK migraine community in disappointment and outrage over NICE’s decision to deny its first review of the new CGRP inhibitors. This decision reflects institutions and individuals that continue to inappropriately underestimate the disability caused by migraine disease and a society that discriminates and under-values pain and its impact on the people living this invisible disease.
“NICE’s decision is a major blow to those with migraine and all of us looking for effective treatment options around the globe,” said Kevin Lenaburg, Executive Director of CHAMP. “Once again we see regulators putting costs above care. It is cruel that NICE acknowledges that Aimovig is “clinically proven” and shows “promising” results, and then denies coverage to the 500,000 Britons living with the pain and disability of migraine disease.”
CHAMP urges our migraine allies in the UK to vigorously contest this draft guidance and we offer our support in any way that would be helpful. All stakeholders need to work together to properly consider all the costs that migraine disease inflicts on society and appropriately cover medicines that help people with migraine to live full and productive lives.